Hereditary epilepsy - Insights
Find out how we perform in-depth mutation and copy number variant analysis to determine causes of epilepsy and identify potential treatment options.
April 2023 - Ophthalmic Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Ophthalmic Pathology.
Hepatocellular Carcinoma Risk Panel with GALAD Score - Insights
In this “Hot Topic,” Joshua Bornhorst, Ph.D., assistant professor of laboratory medicine and pathology at Mayo Clinic, reviews biomarker component testing for hepatocellular carcinoma, explains the GALAD score, and explores GALAD score...
Pathways Case Studies: May 2023 - Insights
This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for May include the following sub-specialties: Cytopathology, Gastroenterology...
May 2023 - Renal Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Renal Pathology.
July 2023 - Molecular Pathology - Insights
This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Molecular Pathology.
Therapeutic drug monitoring - Insights
Learn more about Mayo Clinic Laboratories’ clinically driven approach to therapeutic drug monitoring.
For children who require thiopurine medications (such as azathioprine and 6-mercaptopurine) to treat inflammatory bowel disease (IBD), understanding how thiopurines are metabolized is vital to choosing the most effective treatment. Because...
Mayo Clinic Laboratories cerebrospinal fluid metagenomic testing uses shotgun metagenomic sequencing to interrogate all microbial DNA and RNA present in a sample and determine the presence of potential pathogens.
February 2023 - Hematopathology Case Two - Insights
This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Hematopathology.
Five Steps to Improve Transfusion Medicine - Insights
Blood transfusion is the most common procedure performed in hospitals in the U.S. Yet published evidence shows significant gaps in clinicians' knowledge of this critical aspect of patient care, including possible adverse reactions that can...
Phlebotomy Top Gun: Order of Draw-Do We Still Care? - Insights
In this month’s “Hot Topic,” Brad Karon, M.D., Ph.D., will cover the need and evidence behind following the order of draw recommendations for routine blood collection. Specifically, does evidence demonstrate a need to collect serum tubes...
testing_algorithm_for_the_screening_and_diagnosis_of_hepatitis_c.pdf
© Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. 02/2022 Hepatitis C: Testing Algorithm for Screening and Diagnosis HCVQN / Hepatitis C Virus (HCV) RNA Detection and Quantification by Real-Time Reverse...
Phlebotomy Top Gun: Drawing Blood from a Patient Receiving Intravenous Fluids - Insights
In this month’s “Hot Topic,” Brad Karon, M.D., Ph.D., presents a case-based scenario on drawing blood from a patient receiving intravenous fluids.
MGMR - Overview: Myasthenia Gravis Evaluation with Muscle-Specific Kinase (MuSK) Reflex, Serum
Diagnosing autoimmune myasthenia gravis (MG) in adults and children Distinguishing autoimmune from congenital MG in adults and children or other acquired forms of neuromuscular junction transmission disorders Establishing a quantitative...
MGLE - Overview: Myasthenia Gravis/Lambert-Eaton Myasthenic Syndrome Evaluation, Serum
Confirming the autoimmune basis of a defect in neuromuscular transmission (eg, myasthenia gravis [MG], Lambert-Eaton myasthenic syndrome [LEMS]) Distinguishing LEMS from autoimmune forms of MG Providing a quantitative autoantibody...
Precision pain management - Insights
Our liquid chromatography-tandem mass spectrometry, high-resolution accurate mass (LC-MS/MS HRAM) screens, and confirmatory testing for controlled substances are available based on the needs of your patients.
March 2021 — Cardiovascular Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Cardiovascular Pathology.
November 2023 - Gastroenterology Pathology Case 1 - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Gastroenterology Pathology.
May 2023 - Cytopathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Cytopathology.
June 2023 - Liver Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Liver Pathology.
Learn more about Mayo Clinic Laboratories’ testing to identify and monitor nicotine use as part of a patient’s nicotine-use cessation treatment plan, before anesthesia/surgery, or as part of insurance policy assessments.
Precision pain management - Insights
Our liquid chromatography-tandem mass spectrometry, high-resolution accurate mass (LC-MS/MS HRAM) screens, and confirmatory testing for controlled substances are available based on the needs of your patients.
Hereditary Alzheimer's disease and dementia - Insights
Learn about our genetic testing for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and CADASIL.
Reframing diagnosis for peripheral neuropathy - Insights
Learn more about how Mayo Clinic Laboratories’ algorithmic testing approach to peripheral neuropathy cuts through diagnostic complexity to provide meaningful answers.
Acquired Neuropathy Diagnostic Algorithm
Acquired Neuropathy Diagnostic Algorithm
AHUSD - Overview: Atypical Hemolytic Uremic Syndrome Complement Panel, Serum and Plasma
Detecting deficiencies in the alternative pathway that can cause atypical-hemolytic uremic syndrome, dense deposit disease, and C3 glomerulonephritis A second-tier test that aids in the differential diagnosis of thrombotic...
Inflammatory Bowel Disease - Mayo Clinic Laboratories
Inflammatory bowel disease (IBD) is typically classified as either Crohn's disease or ulcerative colitis based on clinical features, colonoscopy findings, histologic changes, and the anatomical distribution of disease. In some cases,...
September 2023 - Cytopathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Cytopathology.
Pathways Case Studies: November 2023 - Insights
This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for November include the following sub-specialties: Cardiovascular Pathology,...
Pathways Case Studies: September 2023 - Insights
This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for September include the following sub-specialties: Cardiovascular Pathology,...
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the use of qualitative urine screening assays and quantitative confirmatory testing to determine compliance in pain management patients.
Helicobacter pylori Infection: Serologic Testing Not Recommended [Communiqué] - Insights
Helicobacter pylori (H pylori) infection is among the most common bacterial infections worldwide with approximately one-half of the world’s population infected. Several invasive and noninvasive testing methods are available to detect H...
Seeking, and finding, answers, comfort, and hope: Joe Mondloch - Insights
Joe Mondloch and his wife Sue have existed in a grey area of uncertainty due to the unpredictable autoimmune neurological illness Joe has lived with for the last seven years. Rare, incurable, and debilitating, the newly classified disorder...
Frozen and on Time: Rapid Margin Assessment Helps Prevent Repeat Surgeries - Insights
A breakthrough in pathology, achieved more than a century ago (allegedly on a frozen window ledge in Rochester, Minnesota) has evolved into an innovative aspect of care at Mayo Clinic. Mayo is one of the only medical centers in the United...
Seeking, and finding, answers, comfort, and hope: Joe Mondloch - Insights
Joe Mondloch and his wife Sue have existed in a grey area of uncertainty due to the unpredictable autoimmune neurological illness Joe has lived with for the last seven years. Rare, incurable, and debilitating, the newly classified disorder...
Modified two-tiered testing for Lyme disease - Insights
In this month’s “Hot Topic,” Elitza Theel, Ph.D., discusses the modified two-tiered testing algorithm for Lyme disease entirely based on enzyme immunoassays (EIA).
The exponential increase in the number of diagnostic tests available to physicians (in dermatopathology as well as other medical specialties) can be overwhelming, according to a new multi-institutional study co-published in the Journal of...
In this month's "Hot Topic," Robin Patel, M.D., discusses how the use of multiplex tests may reduce the turnaround time for identifying the cause of bloodstream infections, and how this might impact antibiotic stewardship and patient...
Mayo Clinic Laboratories’ robust portfolio of clinically supported assays to test for marijuana use is consistent with professional recommendations.
MCL Neuromuscular Flyer MC2775647
MCL Neuromuscular Flyer HEREDITARY NEUROMUSCULAR DISORDERS ENHANCE DIAGNOSIS PHENOTYPIC DIRECTED TESTING emergence advanced molecular testing technologies improved detection
Our pharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.
Our pharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.
Our pharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.
Our pharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.
Syndromic Testing for Infectious Diseases: Respiratory Infections - Insights
In this month's "Hot Topic," Matthew Binnicker, Ph.D., discusses the use of multiplex panels for the diagnosis of respiratory infections and focuses on the clinical utility of these tests in the setting of upper respiratory tract...
Diagnostic ecosystem boosts access to timely Alzheimer's disease testing - Insights
Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic...
Cross-laboratory collaboration accelerates gold-standard SRA testing - Insights
Utilizing testing capabilities of two separate laboratory facilities, Mayo Clinic Laboratories’ new serotonin release assay (SRA) is a gold-standard test supported by decades of clinical hematopathologic experience and advanced mass...
Learn more about Mayo Clinic Laboratories testing for pregnancy loss, which can help determine causes and risk of recurrence for future pregnancies.
Helicobacter pylori testing: 2021 update - Insights
In this month’s Hot Topic, Robin Patel, M.D., discusses Mayo Clinic Laboratories’ new PCR assay for detection of Helicobacter pylori detection and determination of clarithromycin resistance directly from stool.